Idioma:

Suppression of Acquired Docetaxel Resistance in Prostate Cancer through Depletion of Notch- and Hedgehog-Dependent Tumor-Initiating Cells

Domingo-Domenech, Josep ; Vidal, Samuel J. ; Rodriguez-Bravo, Veronica ; Castillo-Martin, Mireia ; Quinn, S. Aidan ; Rodriguez-Barrueco, Ruth ; Bonal, Dennis M. ; Charytonowicz, Elizabeth ; Gladoun, Nataliya ; de la Iglesia-Vicente, Janis ; Petrylak, Daniel P. ; Benson, Mitchell C. ; Silva, Jose M. ; Cordon-Cardo, Carlos

Cancer cell, 2012-09, Vol.22 (3), p.373-388 [Periódico revisado por pares]

United States: Elsevier Inc

Texto completo disponível

Citações Citado por

Enviar para

Título:
Suppression of Acquired Docetaxel Resistance in Prostate Cancer through Depletion of Notch- and Hedgehog-Dependent Tumor-Initiating Cells
Autor: Domingo-Domenech, Josep ; Vidal, Samuel J. ; Rodriguez-Bravo, Veronica ; Castillo-Martin, Mireia ; Quinn, S. Aidan ; Rodriguez-Barrueco, Ruth ; Bonal, Dennis M. ; Charytonowicz, Elizabeth ; Gladoun, Nataliya ; de la Iglesia-Vicente, Janis ; Petrylak, Daniel P. ; Benson, Mitchell C. ; Silva, Jose M. ; Cordon-Cardo, Carlos
Assuntos: Animals ; Apoptosis ; Cell Line, Tumor ; Disease Progression ; Drug Resistance, Neoplasm ; Hedgehog Proteins - genetics ; Hedgehog Proteins - metabolism ; Humans ; Male ; Mice ; Mice, Inbred NOD ; Mice, SCID ; Molecular Sequence Data ; Neoplastic Stem Cells - metabolism ; Neoplastic Stem Cells - pathology ; Prostatic Neoplasms - drug therapy ; Prostatic Neoplasms - metabolism ; Prostatic Neoplasms - pathology ; Proto-Oncogene Proteins c-akt - antagonists & inhibitors ; Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors ; Receptors, Notch - genetics ; Receptors, Notch - metabolism ; Signal Transduction ; Taxoids - pharmacology ; Xenograft Model Antitumor Assays
É parte de: Cancer cell, 2012-09, Vol.22 (3), p.373-388
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Present address: Molecular Biology Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA
Present address: Department of Pathology, Mount Sinai School of Medicine, New York, NY 10029, USA
Descrição: Acquired resistance to Docetaxel precedes fatality in hormone-refractory prostate cancer (HRPC). However, strategies that target Docetaxel resistant cells remain elusive. Using in vitro and in vivo models, we identified a subpopulation of cells that survive Docetaxel exposure. This subpopulation lacks differentiation markers and HLA class I (HLAI) antigens, while overexpressing the Notch and Hedgehog signaling pathways. These cells were found in prostate cancer tissues and were related to tumor aggressiveness and poor patient prognosis. Notably, targeting Notch and Hedgehog signaling depleted this population through inhibition of the survival molecules AKT and Bcl-2, suggesting a therapeutic strategy for abrogating Docetaxel resistance in HRPC. Finally, these cells exhibited potent tumor-initiating capacity, establishing a link between chemotherapy resistance and tumor progression. ► Docetaxel-resistant cells are undifferentiated and overexpress developmental pathways ► Docetaxel-resistant cells associate with poor clinical outcome in prostate cancer ► Notch and Hedgehog signaling inhibition depletes Docetaxel-resistant cells ► Docetaxel-resistant cells have high tumor-initiating capacity
Editor: United States: Elsevier Inc
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Suppression of Acquired Docetaxel Resistance in Prostate Cancer through Depletion of Notch- and Hedgehog-Dependent Tumor-Initiating Cells

United States: Elsevier Inc

Buscando em bases de dados remotas. Favor aguardar.